Foghorn Therapeutics Inc. (FHTX)
Largest Insider Buys in Sector
FHTX Stock Price History Chart
FHTX Stock Performance
About Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome; and FHD-609, a small molecule protein degrader for BRD9 to treat patients with synovial sarcoma. The company is also developing an enzymatic inhibitor and a protein degrader as selective modulators of BRM; and ARID1B selective modulators for the treatment of ovarian, endometrial, colorectal, bladder, and gastric cancers. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and with Loxo Oncology to create novel oncology medicines. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Insider Activity of Foghorn Therapeutics Inc.
Over the last 12 months, insiders at Foghorn Therapeutics Inc. have bought $0 and sold $853,289 worth of Foghorn Therapeutics Inc. stock.
On average, over the past 5 years, insiders at Foghorn Therapeutics Inc. have bought $4.89M and sold $1.71M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 150,000 shares for transaction amount of $2.4M was made by Flagship Ventures Fund V General Partner LLC (10 percent owner) on 2020‑10‑27.
List of Insider Buy and Sell Transactions, Foghorn Therapeutics Inc.
| 2024-09-23 | Sale | Chief People Officer | 857 0.0017% | $10.17 | $8,716 | -15.24% | ||
| 2024-09-20 | Sale | Chief People Officer | 35,756 0.0649% | $10.04 | $358,990 | -20.47% | ||
| 2024-09-18 | Sale | Chief People Officer | 11,574 0.022% | $10.05 | $116,319 | -16.32% | ||
| 2024-09-17 | Sale | Chief People Officer | 10,272 0.0189% | $10.04 | $103,131 | -18.60% | ||
| 2024-09-16 | Sale | Chief People Officer | 400 0.0008% | $10.00 | $4,000 | -13.39% | ||
| 2024-09-09 | Sale | Chief Scientific Officer | 20,000 0.0366% | $9.50 | $190,000 | -13.82% | ||
| 2024-03-11 | Sale | Chief Strategy/Bus Ops Officer | 11,000 0.0249% | $6.56 | $72,134 | -2.91% | ||
| 2023-08-16 | Sale | Chief Medical Officer | 311,297 0.6823% | $8.25 | $2.57M | -35.39% | ||
| 2020-10-27 | 10 percent owner | 150,000 1.3579% | $16.00 | $2.4M | -20.50% | |||
| 2020-10-27 | 150,000 1.3579% | $16.00 | $2.4M | -20.50% | ||||
| 2020-10-27 | Chief Scientific Officer | 5,500 0.0498% | $16.00 | $88,000 | -20.50% |
Insider Historical Profitability
| Bellon Steven F. | Chief Scientific Officer | 101957 0.1834% | $7.65 | 0 | 1 | |
| Cavalie Fanny | Chief Strategy/Bus Ops Officer | 75992 0.1367% | $7.65 | 0 | 1 | |
| Costa Carlos | Chief People Officer | 0 0% | $7.65 | 0 | 5 | |
| Flagship Ventures Fund V General Partner LLC | 10 percent owner | 9330878 16.7842% | $7.65 | 1 | 0 | <0.0001% |
| Abu Dhabi Investment Authority | 1231081 2.2144% | $7.65 | 1 | 0 | <0.0001% | |
| DECICCO CARL | Chief Scientific Officer | 258397 0.4648% | $7.65 | 1 | 0 | <0.0001% |
| Agresta Samuel | Chief Medical Officer | 0 0% | $7.65 | 0 | 1 |
Institutional Investor Ownership
| Flagship Pioneering | $85.04M | 22.91 | 12.67M | 0% | +$0 | 5.58 | |
| Fidelity Investments | $18.06M | 4.86 | 2.69M | -4.23% | -$797,637.81 | <0.01 | |
| Raymond James Associates | $14.97M | 4.03 | 2.23M | +7.84% | +$1.09M | 0.01 | |
| Euclidean Capital Llc | $10.56M | 2.84 | 1.57M | 0% | +$0 | 1.36 | |
| BlackRock | $8.83M | 2.38 | 1.32M | +0.73% | +$63,765.13 | <0.0001 | |
| The Vanguard Group | $7.4M | 1.99 | 1.1M | +7.55% | +$519,219.73 | <0.0001 | |
| Artal Group S A | $4.84M | 1.3 | 720,720 | 0% | +$0 | 0.02 | |
| Alphabet | $3.36M | 0.91 | 500,901 | 0% | +$0 | 0.03 | |
| Geode Capital Management | $3.01M | 0.81 | 448,411 | +0.01% | +$409.36 | <0.0001 | |
| State Street | $2.94M | 0.79 | 437,664 | +3.56% | +$100,878.13 | <0.0001 | |
| Point72 Asset Management | $2.93M | 0.79 | 437,369 | -19.01% | -$688,654.01 | <0.01 | |
| Birchview Capital Lp | $2.15M | 0.58 | 320,930 | 0% | +$0 | 0.12 | |
| Driehaus Capital Management LLC | $1.88M | 0.51 | 280,382 | -18.43% | -$424,997.93 | 0.02 | |
| Jacobs Levy Equity Management | $1.45M | 0.39 | 216,270 | +101.05% | +$729,377.15 | 0.01 | |
| Northern Trust | $1.31M | 0.35 | 195,242 | -2.02% | -$27,054.72 | <0.0001 | |
| Sio Capital Management LLC | $816,419.00 | 0.22 | 121,672 | 0% | +$0 | 0.29 | |
| Panagora | $673,047.00 | 0.18 | 100,305 | +3.39% | +$22,062.49 | <0.01 | |
| Morgan Stanley | $503,049.00 | 0.14 | 74,970 | -28.68% | -$202,259.65 | <0.0001 | |
| Millennium Management LLC | $416,335.00 | 0.11 | 62,047 | New | +$416,335.00 | <0.0001 | |
| BNY Mellon | $407,761.00 | 0.11 | 60,769 | +6.24% | +$23,961.47 | <0.0001 | |
| Invesco | $376,042.00 | 0.1 | 56,042 | New | +$376,042.00 | <0.0001 | |
| Charles Schwab | $372,016.00 | 0.1 | 55,442 | 0% | +$0 | <0.0001 | |
| Nuveen | $362,092.00 | 0.1 | 53,963 | 0% | +$0 | <0.0001 | |
| Exchange Traded Concepts, LLC | $316,021.00 | 0.09 | 47,097 | +118.7% | +$171,521.09 | 0.01 | |
| Baker Bros Advisors LP | $302,131.00 | 0.08 | 45,027 | 0% | +$0 | <0.01 | |
| Acadian Asset Management | $283,000.00 | 0.08 | 42,367 | New | +$283,000.00 | <0.01 | |
| Marshall Wace | $245,089.00 | 0.07 | 36,526 | New | +$245,089.00 | <0.0001 | |
| ALTA WEALTH ADVISORS | $201,515.00 | 0.05 | 30,032 | 0% | +$0 | 0.1 | |
| RhumbLine Advisers | $179,411.00 | 0.05 | 26,739 | +3% | +$5,220.16 | <0.0001 | |
| Cornercap Investment Counsel Inc | $173,245.00 | 0.05 | 25,819 | 0% | +$0 | 0.03 | |
| Citadel Advisors LLC | $160,859.00 | 0.04 | 23,973 | New | +$160,859.00 | <0.0001 | |
| Gsa Capital Partners Llp | $147,000.00 | 0.04 | 21,855 | -47.08% | -$130,756.35 | 0.01 | |
| UBS | $136,709.00 | 0.04 | 20,374 | -12.86% | -$20,176.89 | <0.0001 | |
| Barclays | $129,000.00 | 0.04 | 19,242 | -41.52% | -$91,591.21 | <0.0001 | |
| Susquehanna International Group | $107,897.00 | 0.03 | 16,080 | +41.91% | +$31,865.85 | <0.0001 | |
| HSBC | $105,958.00 | 0.03 | 15,791 | +16.21% | +$14,782.18 | <0.0001 | |
| JPMorgan Chase | $94,196.00 | 0.03 | 14,038 | +6.54% | +$5,784.08 | <0.0001 | |
| Xtx Topco Ltd | $90,236.00 | 0.02 | 13,448 | New | +$90,236.00 | <0.01 | |
| State Board of Administration of Florida | $77,339.00 | 0.02 | 12,474 | New | +$77,339.00 | <0.0001 | |
| Bank of America | $85,406.00 | 0.02 | 12,728 | -56.22% | -$109,676.39 | <0.0001 | |
| Goldman Sachs | $76,635.00 | 0.02 | 11,421 | -19.8% | -$18,922.22 | <0.0001 | |
| Fiduciary Trust Co | $72,998.00 | 0.02 | 10,879 | 0% | +$0 | <0.01 | |
| American International Group | $67,221.00 | 0.02 | 10,018 | -0.85% | -$577.06 | <0.0001 | |
| AllianceBernstein | $67,436.00 | 0.02 | 10,050 | 0% | +$0 | <0.0001 | |
| Deutsche Bank | $64,376.00 | 0.02 | 9,594 | -3.99% | -$2,677.30 | <0.0001 | |
| Royal Bank of Canada | $57,000.00 | 0.02 | 8,448 | +29.95% | +$13,136.72 | <0.0001 | |
| Wells Fargo | $40,790.00 | 0.01 | 6,079 | +15.44% | +$5,455.22 | <0.0001 | |
| NISA Investment Advisors, LLC | $33,577.00 | 0.01 | 5,004 | +0.08% | +$26.84 | <0.0001 | |
| Citigroup | $22,714.00 | 0.01 | 3,385 | +15.41% | +$3,033.01 | <0.0001 | |
| New York State Common Retirement Fund | $16,000.00 | <0.01 | 2,422 | +28.69% | +$3,567.30 | <0.0001 |